Charles River Laboratories, Michael J. Fox Foundation Extend Research Partnership
Charles River Laboratories International and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) extended their collaboration to accelerate…
Articles by José Lopes, PhD
First Parkinson’s Patient Treated with Insightec’s Incisionless Brain Therapy
Insightec has treated the first patient in a pivotal study of its non-invasive ultrasound therapy, ExAblate Neuro, for patients with…
Better Understanding of Parkinson’s Psychosis Needed to Develop New Therapies, Study Suggests
Improved understanding of Parkinson’s disease psychosis (PDP) and a unified approach for its clinical evaluation are key for developing…
Lightning Can Affect Deep Brain Stimulation Devices Used to Treat Parkinson’s, Study Finds
Nearly lightning strikes might affect the systems used for deep brain stimulation (DBS) in Parkinson’s patients and possibly the implants…
Rabies Virus May Hold Key for Efficient Therapies in Parkinson’s, Study Suggests
New nanoparticles containing a specific part of the rabies virus may improve brain-targeting therapy in Parkinson’s patients, study suggests.
Concussions, Other Mild Brain Injuries Raise Parkinson’s Risk, Study Reports
A mild traumatic brain injury (TBI), including a concussion, can increase a person’s risk of developing Parkinson’s disease by more…
Molecule from Fat Burning Linked to Protein Clumps That Typify Parkinson’s in Study
A molecule created by the brain burning fat for fuel can accumulate in some people and turn toxic, playing a…
#AAN2018 — Vercise Deep Brain Stimulation Improves Motor Control in Parkinson’s Patients, Trial Shows
People with Parkinson’s disease show better motor control, longer “on” periods, and an improved quality of life when treated with…
Phase 2 Study of Potential Oral Therapy for Parkinson’s Dementia, Anavex 2-73, Planned
Anavex Life Sciences is planning to open a Phase 2 clinical trial testing Anavex 2-73, a potential oral treatment…
#AAN2018 – Real-life Use Supports Nuplazid’s Safety, Efficacy in Treating Parkinson’s Psychosis
Nuplazid (pimavanserin) is well-tolerated and can lead to clinical improvement in people with Parkinson’s disease psychosis (PDP), according to…